Literature DB >> 17960513

The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs.

N Ogawa1, T Yamaguchi, S Yano, M Yamauchi, M Yamamoto, T Sugimoto.   

Abstract

Type 1 diabetes mellitus is known to be associated with reduced bone mass and increased bone fractures. This is thought to be due to a decrease in osteoblastic bone formation rather than an increase in osteoclastic bone resorption, but the precise mechanism is unknown. In this study, we examined whether or not high glucose or advanced glycation end-products (AGEs), which play key roles in the pathogenesis and complications of diabetes, affect the differentiation of osteoblastic MC3T3-E1 cells. First, MC3T3-E1 cells were incubated in media containing either 22 mM glucose, 22 mM mannitol, 300 microg/ml AGE2, or 300 microg/ml AGE3. Each of these agents alone did not affect the mineralization of the cells by von Kossa staining and Alizarin red staining. However, high glucose but not mannitol or AGEs markedly increased mRNA expression of AGE receptor (RAGE) by real-time PCR. Next, we examined the combined effects of high glucose and AGEs on the differentiation of MC3T3-E1 cells. The combination of 22 mM glucose and 300 microg/ml AGE2 significantly inhibited the mineralization of MC3T3-E1 cells, and 22 mM glucose in combination with either 300 microg/ml AGE2 or AGE3 apparently decreased osteocalcin mRNA expression. These results suggest that high glucose or AGEs alone might have no effect on osteoblastic differentiation, but their combination could additionally or synergistically inhibit osteoblastic mineralization through glucose-induced increase in RAGE expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17960513     DOI: 10.1055/s-2007-991157

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  40 in total

1.  High glucose promotes mineralization via bone morphogenetic protein 4-Smad signals in early stage of osteoblast differentiation.

Authors:  Ayumu Takeno; Ippei Kanazawa; Ken-Ichiro Tanaka; Masakazu Notsu; Keizo Kanasaki; Takamasa Oono; Yoshihiro Ogawa; Toshitsugu Sugimoto
Journal:  Diabetol Int       Date:  2020-08-30

Review 2.  Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts.

Authors:  Evangelia Kalaitzoglou; Iuliana Popescu; R Clay Bunn; John L Fowlkes; Kathryn M Thrailkill
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

3.  Bone fragility in type 2 diabetes mellitus.

Authors:  Toru Yamaguchi
Journal:  World J Orthop       Date:  2010-11-18

4.  Antioxidant effect of myricitrin on hyperglycemia-induced oxidative stress in C2C12 cell.

Authors:  Akram Ahangarpour; Ali Akbar Oroojan; Layasadat Khorsandi; Maryam Kouchak; Mohammad Badavi
Journal:  Cell Stress Chaperones       Date:  2018-03-07       Impact factor: 3.667

5.  Chronic hyperglycemia affects bone metabolism in adult zebrafish scale model.

Authors:  Marta Carnovali; Livio Luzi; Giuseppe Banfi; Massimo Mariotti
Journal:  Endocrine       Date:  2016-10-01       Impact factor: 3.633

Review 6.  A new perspective on mechanisms governing skeletal complications in type 1 diabetes.

Authors:  Zeynep Seref-Ferlengez; Sylvia O Suadicani; Mia M Thi
Journal:  Ann N Y Acad Sci       Date:  2016-08-29       Impact factor: 5.691

7.  Fracture risk is increased by the complication of hypertension and treatment with calcium channel blockers in postmenopausal women with type 2 diabetes.

Authors:  Shin Takaoka; Toru Yamaguchi; Ken-Ichiro Tanaka; Miwa Morita; Masahiro Yamamoto; Mika Yamauchi; Shozo Yano; Toshitsugu Sugimoto
Journal:  J Bone Miner Metab       Date:  2012-10-17       Impact factor: 2.626

Review 8.  Diabetes and Its Effect on Bone and Fracture Healing.

Authors:  Hongli Jiao; E Xiao; Dana T Graves
Journal:  Curr Osteoporos Rep       Date:  2015-10       Impact factor: 5.096

Review 9.  Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus.

Authors:  M Saito; K Marumo
Journal:  Osteoporos Int       Date:  2010-02       Impact factor: 4.507

10.  Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes.

Authors:  Masahiro Yamamoto; Toru Yamaguchi; Mika Yamauchi; Toshitsugu Sugimoto
Journal:  Diabetes Care       Date:  2009-09-14       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.